Repligen Investor Presentation 2022 Bioprocessing

Repligen is a bioprocessing solutions provider offering disruptive technologies for efficient, single-use, flexible manufacturing of biological drugs. The company generated approximately $660M in revenue in 2021 with a 38% five-year CAGR, leveraging a >$8B TAM across diverse customer bases and drug modalities including monoclonal antibodies.